Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

728
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
728
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

281
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
281
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

638
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
638

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primulagenin A is a potent inverse agonist of the nuclear receptor RAR-related orphan receptor gamma (ROR<i>γ</i>).

Acta pharmaceutica Sinica. B·2026
Same author

Goals, cheers, and gamma-GT: Do football tournaments affect laboratory parameters?

Frontiers in public health·2026
Same author

Stage-Specific Drivers of Clinical Progression in Advanced Chronic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Utilization Patterns of Hospital Biobank Samples: Time to First Use and Material-Specific Demand.

Journal of clinical medicine·2026
Same author

Comparison of People with Hemophilia A and Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulation by Thrombin Generation.

Thrombosis and haemostasis·2026
Same author

Fibroblast growth factor 23 is associated with cardiac disease severity in transthyretin amyloid cardiomyopathy.

Scientific reports·2026

Related Experiment Video

Updated: Mar 22, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Lupus-anticoagulant testing at NOAC trough levels.

Franz Ratzinger, Mona Lang, Sabine Belik

  • 1Peter Quehenberger, Medical University of Vienna, Department of Laboratory Medicine, Waehringer Guertel 18-20, 1090 Vienna, Austria, Tel.: +43 1 40400 53830, Fax: +43 1 40400 53920,

Thrombosis and Haemostasis
|April 15, 2016
PubMed
Summary

Non-vitamin K antagonist oral anticoagulants (NOACs) can cause false positives in lupus anticoagulant (LA) testing, even at low concentrations. Avoid LA testing in patients taking NOACs due to unreliable results.

Keywords:
Coagulationanticoagulantlaboratory testinglupus anticoagulantnon-vitamin K antagonist oral anticoagulants

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

67
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 22, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

67
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Area of Science:

  • Clinical Chemistry
  • Hematology
  • Thrombosis and Hemostasis

Background:

  • Non-vitamin K antagonist oral anticoagulants (NOACs) like rivaroxaban, apixaban, and dabigatran are widely used for anticoagulation.
  • These NOACs can interfere with laboratory coagulation tests, complicating diagnostic interpretations.
  • Lupus anticoagulant (LA) testing is crucial for diagnosing antiphospholipid syndrome but may be affected by NOACs.

Purpose of the Study:

  • To investigate the potential interference of NOACs at trough concentrations in lupus anticoagulant (LA) testing.
  • To determine the accuracy of LA testing in patients receiving rivaroxaban, apixaban, or dabigatran.

Main Methods:

  • Citrate plasma from 30 healthy volunteers was spiked with rivaroxaban, apixaban, or dabigatran at various low concentrations.
  • NOAC concentrations were verified using surrogate tests.
  • A standard LA testing procedure (screening, mixing, and confirmatory tests) was performed on spiked samples.

Main Results:

  • Dabigatran (≥12.5 ng/ml) caused significant prolongations in aPTT-LA and dRVVT, leading to 43.3% false positives.
  • Rivaroxaban (≥7.5 ng/ml) primarily affected dRVVT, causing 30.0% false positives in confirmatory tests.
  • Apixaban (≥18.75 ng/ml) prolonged dRVVT, resulting in up to 20.7% false positives, without a clear dose-dependent increase.

Conclusions:

  • The rate of false positive results in LA testing is unacceptably high at typical trough NOAC levels.
  • LA testing should be avoided in patients undergoing NOAC therapy due to significant interference.
  • Interference can occur even below the lower limit of quantification of commercial NOAC assays.